Brenipatide clinical trials
Brenipatide is named as an intervention in 14 current clinical trials in our USA, China, Japan, UK, Germany, Canada, Mexico, South Korea, Taiwan, Poland, Brazil, Belgium, Spain, India, Australia, France, Denmark, Austria, Czechia and Netherlands registers. 12 are recruiting patients now. The most common phase is Phase 2. The lead sponsor is Eli Lilly and Company. The most-studied condition is Alcohol Use Disorder. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
Patient leaflets for Brenipatide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Brenipatide
14 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Brenipatide in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Brenipatide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
J2S-MC-GZMV: A Phase 2, Multicenter, Randomized, Double-Blind, 52-week Study to Investigate the Efficacy and Safety of Brenipatide Compared With Placebo for the Treatment of Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)
2026-525480-41-00 · Respiratory Tract Diseases
|
Phase 2 | Ongoing | Eli Lilly & Co | Denmark, France, Romania + 5 more |
Conditions studied with Brenipatide
13 conditionsAll 13 conditions
| Condition (as registered) | Trials |
|---|---|
| Alcohol Use Disorder | 2 |
| Depressive Disorder, Major | 2 |
| Irritable Bowel Syndrome | 2 |
| Obesity | 2 |
| Overweight | 2 |
| Opioid Use Disorder | 1 |
| Diarrhea | 1 |
| Constipation | 1 |
| Pulmonary Disease, Chronic Obstructive | 1 |
| Asthma | 1 |
| Smoking | 1 |
| Schizophrenia | 1 |
| Bipolar Disorder | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 14 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Brenipatide trials
How many clinical trials are testing Brenipatide?
14 current trials in our USA, China, Japan, UK, Germany, Canada, Mexico, South Korea, Taiwan, Poland, Brazil, Belgium, Spain, India, Australia, France, Denmark, Austria, Czechia and Netherlands registers name Brenipatide (also registered as LY3537031) as a drug or biological intervention, as of the registry sync on 8 November 2026. Completed and withdrawn studies are not counted.
Are Brenipatide trials recruiting patients?
Yes. 12 of the 14 trials are recruiting: 12 with sites in USA, 11 with sites in China, 11 with sites in Japan, 8 with sites in UK, 7 with sites in Germany, 7 with sites in Canada, 7 with sites in Mexico, 5 with sites in South Korea, 5 with sites in Taiwan, 5 with sites in Poland, 5 with sites in Brazil, 4 with sites in Belgium, 4 with sites in Spain, 4 with sites in India, 2 with sites in Australia, 2 with sites in France, 1 with sites in Denmark, 1 with sites in Austria, 1 with sites in Czechia and 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Brenipatide clinical trials?
The lead sponsor is Eli Lilly and Company. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Brenipatide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Brenipatide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Brenipatide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 8 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.